

## Disclosure Results

Scenesse

European Marketing Authorisation Holder: Clinuvel UK Limited

phase	total complete by 31 July 2016	un-evaluable	evaluable	disclosed in 12 month timeframe	disclosed percentage at 12 months	complete by 31 July 2016	disclosed at 31 July 2016	disclosure percentage at 31st July 2016
phase I & II	10	0	10	6	60%	10	6	60%
phase III	7	1	6	4	67%	6	4	67%
phase IV	0	0	0	0		0	0	
other	0	0	0	0		0	0	
<b>total</b>	<b>17</b>	<b>1</b>	<b>16</b>	<b>10</b>	<b>63%</b>	<b>16</b>	<b>10</b>	<b>63%</b>

**Footnote:** Four phase II trials (carried out in Italy; Denmark & Finland; Australia; and Austria, Belgium, France, Germany, Italy, Sweden & Switzerland respectively), and two phase III trials (carried out in Belgium & Netherlands and Belgium, Germany & Netherlands respectively) remained undisclosed at 31 July 2016. (The company did not provide further information on these trials).

### Key to columns in table above:

total complete by 31 July 2016 = total number of company-sponsored trials identified which were completed by 31 July 2016

unevaluable = trials with completion date within the last 12 months, or key dates missing - excluded from the analysis

evaluable = trials with all criteria present including dates; hence the base number of trials evaluated for the assessment

disclosed in 12 month timeframe = evaluable trials which were disclosed within the target 12 months\*

disclosed percentage at 12 months = proportion of evaluable trials which were disclosed within 12 months\*

complete before 31 July 2016 = number of evaluable trials completed before 31 July 2016

disclosed at 31 July 2016 = number of evaluable trials with results disclosed by 31 July 2016

disclosure percentage at 31 July 2016 = proportion of evaluable trials which were disclosed by 31 July 2016

[\* 12 months measured from the later of: the first date of regulatory approval (in Europe or the US) or the trial completion date]